N/A N=64 Treatment of Peritonitis in Automated Peritoneal Dialysis
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Intra-abdominal Pressure in Peritoneal Dialysis Patients
Peritoneal Dialysis
Primary: Intra-Abdominal Pressure (IAP) — -0.5; -0.2; -1.2 mm Hg
N/A N=671 Prevention of Peritonitis in Peritoneal Dialysis
Kidney Failure, Chronic · Peritoneal Dialysis-associated Peritonitis · Dialysis Capd Infection
Primary: Time to the First Dialysis-associated Peritonitis Episode in the Retraining Group and the Control Group — 381; 368 Days to first peritonitis episode — p=0.51
N/A N=22 Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure
Hypoplastic Left Heart Syndrome
Primary: Time to First Post-operative Negative 24 Hour Fluid Balance — 2.7; 2.67 Days
N/A N=73 Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass
Acute Kidney Injury
Primary: Number of Participants With Negative Fluid Balance on Postop Day 1 — 21; 29 Participants
Phase 4 N=7 Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
Continuous Ambulatory Peritoneal Dialysis · End Stage Renal Disease
Primary: Volume of Distribution, Central Compartment (Vc) — 2.78 Liters (L)
Phase 1 N=4 Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis
Peritoneal Dialysis-associated Peritonitis
Primary: Maximum Total Plasma Concentration (Cmax) — 28.7 mg/L
Phase 4 N=10 Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients
Infectious Peritonitis
Primary: Determine Dalbavancin Plasma Area Under the Curve in Peritoneal Dialysis Patients After Intravenous and Intraperitoneal Administration — 40573.2; 13532.3 mg*h/L
Phase 2 N=4 L-Carnitine in Peritoneal Dialysis
End-Stage Renal Disease
Primary: Long Dwell Ultrafiltration — 2167 milliliters
N/A N=1,075 Quality of Life and Depression in Dialysis Patients
Chronic Kidney Disease Stage 5
Primary: Change of Kidney Disease Quality of Life Short Form 1.3 (KDQOL SF 1.3) Score and Beck Depression Inventory(BDI) Score From Visit 1 Period — 1.22; -1.50; 1.62; 0.46 units…
N/A N=21 Lung Ultrasound in PD Patients
Peritoneal Dialysis · Hypervolemia · VEGF Overexpression
Primary: Association Between Number of Kerley B Lines by Ultrasound and Serum VEGF-C Level (pg/ml) by Enzyme-linked Immunosorbent Assay — 0.29; 0.25; 0.33 ng/ml — p=0.039
Phase 4 N=55 Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
Hyperphosphatemia
Primary: Phosphorus Levels — 5.3; 5.6; 5.4; 6 mg/dL
Phase 4 N=149 Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Exploring the Effectiveness and Safety of Amino Acid Peritoneal Dialysis Solution
Primary: Blood Albumin — 4.02 g/L — p=<0.0125
N/A N=7 Direct Peritoneal Resuscitation Effects in the Damage Control Patient
Traumatic Injury
Primary: Number of Participants With Morbidity — 0; 0 number of participants
N/A N=208 Improving Care for Peritoneal Dialysis Patients With the CKD-PD App
Kidney Failure, Chronic · Peritoneal Dialysis Complication
Primary: Clinical Interventions for Over Hydration — 473; 164 clinical interventions
N/A N=23 High Water Intake to Slow Progression of Polycystic Kidney Disease
Kidney, Polycystic, Autosomal Dominant
Primary: Change in Urine cAMP Concentration and Urine Osmolality (UOsm) — -2.6; -2.0 fold change in cAMP/UOsm (umol/UOsm)
N/A N=80 Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis
Peritoneal Dialysis Associated Peritonitis
Primary: Complete Cure Rate — 32; 31 Participants
Phase 2 N=20 Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis
Chronic Renal Failure
Primary: Change in Daily Urine Volume From Baseline — 18.3 mL
N/A N=100 Peritoneal Damage in Laparoscopic Surgery
Peritoneal Damage
Primary: Inflammatory Peritoneal Markers — 0.80; 1.14; 4.26; 3.24 log (pg/ml) — p=0.058
Phase 2 N=24 Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
ESRD
Primary: Change in Leucine Disposal Rate (LDR) — -0.011; 0.005; 0.001 mg/kg/min — p=0.37
Phase 4 N=17 Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients
Peritoneal Dialysis Complication · Hyperphosphatemia · Hypoalbuminemia
Primary: Serum Phosphate at Baseline — 7.47 mg/dL
Phase 4 N=47 Beneficial Effect of Probiotics on Chronic Kidney Disease
Chronic Kidney Disease
Primary: the Occurrence of Cardiovascular Event and Peritonitis Events — 0; 0; 0; 0 participants — p=>0.05
Phase 2 N=188 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Abdominal Neoplasm · Colonic Neoplasm · Mesothelioma
Primary: Number of Participants With Disease-free Survival
Phase 3 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
N/A N=86 Recovery Time and Affecting Factors in Hemodialysis Patients
Dialysis; Complications · Life Quality
Primary: Post-dialysis Recovery Time — 278.02 minutes
Phase 1 N=30 Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis
Peritoneal Dialysis (PD) · Anemia · Chronic Kidney Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered in Patients on Chronic Peritoneal Dialysis: Maximum Concentration (Cmax) of Serum Total Iron After Intraperitoneal…
Phase 4 N=251 IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients
ESRD · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Phase 3 N=34 Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Primary: Change in Mean Serum Copeptin From Baseline (a Reflection of Endogenous Vasopressin Production) at Week 2 — -0.86; 0.39 pmole/L — p=<0.01
Phase 2 N=21 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Phase 1 N=8 Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis
Anaemia
Primary: Area Under the Concentration-time Curve (AUC) Over the Dosing Interval (AUC[0-tau]) of GSK1278863 and Its Metabolites — 184.9863; 138.6511; 162.9366; 131.2826 Hour into…